Key result
Sacubitril/valsartan restores LVEF and maintains sinus rhythm in a dilated cardiomyopathy case.
Case Report (n=1)
Sacubitril/valsartan therapy in a young patient with HFrEF, dilated cardiomyopathy, and atrial fibrillation led to significant clinical and echocardiographic improvement over two years.
Hypothesis-generating for sacubitril/valsartan in young DCM; prospective trials needed before clinical adoption.
A novel combination consisting of the neprilysin inhibitor, sacubitril, and the angiotensin-receptor blocker, valsartan (belonging to the newly established class of angiotensin receptor/neprilysin inhibitors), was shown to be effective in the treatment of heart failure (HF) by improving patient clinical status, and reducing re-hospitalization rate and mortality. We report a case of a 29 year old male with HF, dilated cardiomyopathy possibly related to myocarditis and atrial fibrillation with reduced ejection fraction. Sacubitril/valsartan treatment was initiated after two years of standard treatment. In two years, therapy with sacubitril/valsartan led to persistence in sinus rhythm, progressive recovery of ejection fraction, functionality and reduction of cardiac volumes. The patient is currently in good condition and has suspended diuretic therapy in the last six months.
No takes yet. Share an insight, caveat, or question.
Gubelli et al. (2019) conducted a case report in Heart failure, dilated cardiomyopathy, and atrial fibrillation with reduced ejection fraction (n=1). Sacubitril/valsartan was evaluated on Clinical status, ejection fraction, cardiac volumes, and sinus rhythm. Sacubitril/valsartan therapy in a 29-year-old male with heart failure and dilated cardiomyopathy led to persistence in sinus rhythm, recovery of ejection fraction, and reduction of cardiac volumes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: